In order to expand its metabolic diseases portfolio, Roche has agreed to acquire Carmot Therapeutics for US$3.1 B. Through the takeover, Roche will gain access to Carmot’s Chemotype Evolution discovery platform, its R&D portfolio which includes clinical stage incretins to treat obesity in patients with and without diabetes, as well as other preclinical programmes. This acquisition is closely aligned with Roche’s expansion into different therapeutic areas which will help in offsetting declining revenues of some of its key oncology assets.